392 related articles for article (PubMed ID: 32181801)
1. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL
Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801
[No Abstract] [Full Text] [Related]
2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
[TBL] [Abstract][Full Text] [Related]
4. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
Locke FL; Go WY; Neelapu SS
JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
[TBL] [Abstract][Full Text] [Related]
5. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
Jacobson CA; Hunter BD; Redd R; Rodig SJ; Chen PH; Wright K; Lipschitz M; Ritz J; Kamihara Y; Armand P; Nikiforow S; Rogalski M; Maakaron J; Jaglowski S; Maus MV; Chen YB; Abramson JS; Kline J; Budde E; Herrera A; Mei M; Cohen JB; Smith SD; Maloney DG; Gopal AK; Frigault MJ; Acharya UH
J Clin Oncol; 2020 Sep; 38(27):3095-3106. PubMed ID: 32667831
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
Spiegel JY; Dahiya S; Jain MD; Tamaresis J; Nastoupil LJ; Jacobs MT; Ghobadi A; Lin Y; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Goy A; Vu K; Andreadis C; Munoz J; Bennani NN; Vose JM; Dorritie KA; Neelapu SS; Locke FL; Rapoport AP; Hill BT; Miklos DB
Blood; 2021 Apr; 137(13):1832-1835. PubMed ID: 33156925
[No Abstract] [Full Text] [Related]
7. A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
Ghione P; Palomba ML; Ray MD; Limbrick-Oldfield EH; Owen J; Kanters S; Bobillo S; Ribiero MT; Jacobson CA; Neelapu SS; Ghesquieres H; Nahas M; Beygi S; Patel AR; Gribben JG
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e191-e195.e6. PubMed ID: 38365528
[TBL] [Abstract][Full Text] [Related]
8. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract][Full Text] [Related]
9. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
Bouchkouj N; Kasamon YL; de Claro RA; George B; Lin X; Lee S; Blumenthal GM; Bryan W; McKee AE; Pazdur R
Clin Cancer Res; 2019 Mar; 25(6):1702-1708. PubMed ID: 30413526
[TBL] [Abstract][Full Text] [Related]
11. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL
Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751
[TBL] [Abstract][Full Text] [Related]
12. Interim Phase 2 ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL.
Slater H
Oncology (Williston Park); 2020 Jul; 34(7):260. PubMed ID: 32674213
[TBL] [Abstract][Full Text] [Related]
13. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
14. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
15. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
16. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
Shapiro LC; Mustafa J; Lombardo A; Khatun F; Joseph F; Gillick K; Naik A; Elkind R; Abreu M; Fehn K; de Castro A; Pradhan K; Binakaj D; Nelson R; Paroder M; Uehlinger J; Gritsman K; Alejandro Sica R; Kornblum N; Shastri A; Mantzaris I; Bachier-Rodriguez L; Verma A; Braunschweig I; Goldfinger M
Bone Marrow Transplant; 2021 Jul; 56(7):1761-1763. PubMed ID: 33846558
[No Abstract] [Full Text] [Related]
17. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
Chow VA; Gopal AK; Gauthier J; Tseng YD; Turtle CJ; Maloney DG; Shadman M
Blood Adv; 2020 Oct; 4(19):4869-4872. PubMed ID: 33031539
[TBL] [Abstract][Full Text] [Related]
18. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
Badar T; Johnson BD; Hamadani M
Bone Marrow Transplant; 2021 Mar; 56(3):683-685. PubMed ID: 32782349
[No Abstract] [Full Text] [Related]
19. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
[TBL] [Abstract][Full Text] [Related]
20. Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience.
Yuen CA; Hsu JM; Van Besien K; Reshef R; Iwamoto FM; Haggiagi A; Liechty B; Zhang C; Wesley SF; Magge R
J Immunother; 2022 Jun; 45(5):254-262. PubMed ID: 35404315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
